Ascendis Historical Financial Ratios
| ASND Stock | USD 157.94 0.34 0.21% |
Ascendis Pharma is presently reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 187 or Invested Capital of 0.0 will help investors to properly organize and evaluate Ascendis Pharma AS financial condition quickly.
Ascendis |
About Ascendis Financial Ratios Analysis
Ascendis Pharma ASFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Ascendis Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Ascendis financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Ascendis Pharma history.
Ascendis Pharma Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Ascendis Pharma AS stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Ascendis Pharma sales, a figure that is much harder to manipulate than other Ascendis Pharma AS multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Ascendis Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Ascendis Pharma AS current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Ascendis Pharma's Days Of Inventory On Hand is projected to decrease significantly based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 0.48, whereas PTB Ratio is projected to grow to (68.52).
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 0.12 | 0.47 | 0.46 | 0.48 | Days Of Inventory On Hand | 3.9K | 1.7K | 2.4K | 4.4K |
Ascendis Pharma fundamentals Correlations
Click cells to compare fundamentals
Ascendis Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ascendis Pharma fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 993.4 | 833.09 | 124.97 | 24.05 | 20.97 | 19.92 | |
| Ptb Ratio | 8.24 | 7.33 | 24.28 | (44.02) | (72.12) | (68.52) | |
| Days Sales Outstanding | 20.32 | 103.24 | 84.95 | 76.32 | 178.1 | 187.01 | |
| Book Value Per Share | 16.57 | 16.13 | 4.7 | (2.59) | (1.84) | (1.75) | |
| Free Cash Flow Yield | (0.0314) | (0.0424) | (0.0682) | (0.0798) | (0.0732) | (0.0403) | |
| Operating Cash Flow Per Share | (5.36) | (7.63) | (8.84) | (8.3) | (5.34) | (5.61) | |
| Stock Based Compensation To Revenue | 2.8 | 7.65 | 8.59 | 1.25 | 0.25 | 0.26 | |
| Capex To Depreciation | 2.28 | 1.57 | 0.81 | 0.13 | 0.0806 | 0.0765 | |
| Pb Ratio | 8.24 | 7.33 | 24.28 | (44.02) | (72.12) | (68.52) | |
| Ev To Sales | 922.56 | 789.21 | 126.22 | 24.99 | 21.78 | 20.69 | |
| Free Cash Flow Per Share | (5.79) | (8.07) | (9.1) | (8.35) | (5.36) | (5.63) | |
| Roic | (0.35) | (0.45) | (0.6) | (0.71) | (0.37) | (0.39) | |
| Net Income Per Share | (8.28) | (7.0) | (10.4) | (8.55) | (6.59) | (6.92) | |
| Research And Ddevelopement To Revenue | 37.52 | 38.04 | 7.42 | 1.55 | 0.84 | 0.8 | |
| Capex To Revenue | 3.1 | 3.12 | 0.28 | 0.009156 | 0.003924 | 0.003728 | |
| Cash Per Share | 14.2 | 12.45 | 13.12 | 7.1 | 9.76 | 6.15 | |
| Pocfratio | (25.44) | (15.51) | (12.9) | (13.72) | (24.9) | (26.14) | |
| Interest Coverage | (172.38) | (115.52) | (11.13) | (10.34) | (4.26) | (4.47) | |
| Capex To Operating Cash Flow | (0.0794) | (0.058) | (0.0292) | (0.005225) | (0.00466) | (0.004893) | |
| Pfcf Ratio | (23.57) | (14.66) | (12.54) | (13.65) | (24.78) | (26.02) | |
| Income Quality | 0.81 | 0.65 | 1.09 | 0.85 | 0.97 | 1.02 | |
| Roe | (0.5) | (0.43) | (2.21) | 3.3 | 3.58 | 3.76 | |
| Ev To Operating Cash Flow | (23.62) | (14.7) | (13.03) | (14.26) | (25.87) | (27.16) | |
| Pe Ratio | (16.49) | (16.89) | (10.97) | (13.32) | (20.16) | (19.16) | |
| Return On Tangible Assets | (0.32) | (0.43) | (0.36) | (0.54) | (0.59) | (0.34) | |
| Ev To Free Cash Flow | (21.89) | (13.89) | (12.66) | (14.19) | (25.75) | (27.04) | |
| Earnings Yield | (0.0607) | (0.0592) | (0.0912) | (0.0751) | (0.0496) | (0.0521) | |
| Intangibles To Total Assets | 0.005835 | 0.004859 | 0.00443 | 0.005353 | 0.003415 | 0.003244 | |
| Net Debt To E B I T D A | 1.5 | 0.81 | (0.11) | (0.61) | (1.02) | (0.97) | |
| Current Ratio | 14.02 | 8.03 | 5.39 | 3.56 | 1.17 | 1.11 | |
| Tangible Book Value Per Share | 16.46 | 16.04 | 4.61 | (2.67) | (1.91) | (1.82) | |
| Receivables Turnover | 17.97 | 3.54 | 4.3 | 4.78 | 2.05 | 1.95 | |
| Shareholders Equity Per Share | 16.57 | 16.13 | 4.7 | (2.59) | (1.84) | (1.75) | |
| Debt To Equity | 0.11 | 0.12 | 1.93 | (4.42) | (8.1) | (7.7) | |
| Capex Per Share | 0.43 | 0.44 | 0.26 | 0.0434 | 0.0249 | 0.0236 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.06) | Revenue Per Share | Quarterly Revenue Growth 0.263 | Return On Assets | Return On Equity |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.